Login / Signup

Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer.

Zenta SetoNaoki TakataNozomu MurayamaKotaro TokuiSeisuke OkazawaKenta KambaraShingo ImanishiToshiro MiwaRyuji HayashiShoko MatsuiMinehiko Inomata
Published in: Tumori (2020)
Our results suggest that irinotecan monotherapy can be a useful alternative treatment option in the third-line setting for patients with SCLC.
Keyphrases
  • small cell lung cancer
  • combination therapy
  • open label
  • randomized controlled trial
  • study protocol
  • brain metastases